ALIDYA is an anti-lipodystrophic agent. It was developed by Prof. Pasquale Motolese to deal with the genesis and reduction of gynoid lipodystrophy, also known as cellulite. ALIDYA is meant for administration into the deep dermal layer or subcutaneous layer using the mesotherapy method, also known as localized intradermotherapy.
Composed mainly of amino acids, ALIDYA is used to correct and prevent cellulite by restructuring underlying adipose tissue, thus smoothing the surface of the skin and reducing the appearance of dimples and lumps. Research shows it’s possible that cellulite forms because of poor circulation which in turn leads to the deposit of toxic metal ions in cells. The product’s formulation is designed to dissolve toxic elements, drain fluid from the area, and restore normal homeostasis to the cells. By restoring oxygen and other important cell functions, ALIDYA also helps inhibit the formation of cellulite.
ALIDYA is indicated for treating cellulite on the abdomen, thighs, hips, and buttocks, for post-intralipotherapy treatment, and for correcting the appearance of skin after liposuction. The recommended protocol for administering ALIDYA is as a weekly injection for a minimum of 7 and a maximum of 12 sessions. Annual maintenance visits are advisable.
ALIDYA is manufactured by Marllor Biomedical. It is a composed of an oliaminoacidic gel, a-D-(+) glucopyranose, 1-4 glycosidic, etilendiaminotetraacetic sodium, an amino acid buffer system with bicarbonate-sodium corrector, and an osmolarity regulator. ALIDYA comes as a set of 10 vials, with five containing 10 ml of saline solution and five containing 340 mg of powder; the solution and powder must be mixed together.